LEADER 03332nam 2200709z- 450 001 9910566475303321 005 20220506 035 $a(CKB)5680000000037626 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81094 035 $a(oapen)doab81094 035 $a(EXLCZ)995680000000037626 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNew Advances in Melanoma 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (148 p.) 311 08$a3-0365-3453-9 311 08$a3-0365-3454-7 330 $aMelanoma is a very aggressive tumor which is derived from the transformation of pigment-producing cells termed the melanocytes. This cancer type accounts for most of the deaths associated with skin cancer as well as its incidence and is in constant evolution. Because of the rapid and very high metastatic potential of this tumor, melanoma prognosis has been quite poor for a long time. In the past decade, groundbreaking discoveries in the melanoma research field have led to the development of two main treatment strategies: combination therapies targeting specific kinases or combination therapies focused on immune checkpoint inhibitors (ICIs). These treatment approaches have become the standard of care in most cancer centers and significantly improved the prognosis and overall survival of advanced melanoma patients. Nevertheless, many patients do not benefit from or even respond to these treatments. It is therefore essential to better comprehend the phenomenon of drug resistance, immune escape mechanisms, as well as to search for alternative treatment strategies. In addition, strong predictive biomarkers are desperately needed to improve clinical efficacy. The aim of this Special Issue is to present recent advances in the field of melanoma research, in which the abovementioned areas represent the primary focus, and other relevant themes are also discussed. 606 $aPublic health and preventive medicine$2bicssc 610 $aanimal models 610 $aBRAF 610 $adruggable mutations 610 $aembryogenesis 610 $aepidemiology 610 $aimmune escape 610 $aincidence 610 $alung 610 $amelanoblast 610 $amelanoblasts 610 $amelanoma 610 $ametastasis 610 $amice 610 $amicroRNA 610 $amiRNAs 610 $aNF1 610 $aNGS assay 610 $apopulation-based study 610 $apseudotime analysis 610 $areal-time PCR 610 $aRNAseq 610 $asingle-cell transcriptome sequencing 610 $askin cancer 610 $aSpain 610 $atargeted therapies 610 $atranscriptome 610 $atransporter associated with antigen processing 610 $atreatment 610 $atreatment response 610 $aTrp-1 610 $aubiquitination 615 7$aPublic health and preventive medicine 700 $aLarribčre$b Lionel$4edt$01314110 702 $aLarribčre$b Lionel$4oth 906 $aBOOK 912 $a9910566475303321 996 $aNew Advances in Melanoma$93031717 997 $aUNINA